[go: up one dir, main page]

Huard et al., 2014 - Google Patents

Ribavirin/sofosbuvir

Huard et al., 2014

Document ID
264310318593166605
Author
Huard G
et al.
Publication year
Publication venue
Reactions

External Links

Snippet

A prospective study identified 2 patients [ages and sexes not stated] experiencing pruritus or myalgia while receiving ribavirin and sofosbuvir. The patients underwent renal transplant and received hepatitis C treatment [Tx] with renally dosed ribavirin and sofosbuvir 400 mg …
Continue reading at search.proquest.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Similar Documents

Publication Publication Date Title
CY1124307T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF
CL2015003022A1 (en) Use of empagliflozin in the preparation of a useful medication in the treatment of chronic kidney disease
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12015500115B1 (en) Glucagon analogues
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
PH12014500386A1 (en) Combination treatment for hepatitis c
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction
Ascierto et al. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma
MX380835B (en) PAC-1 COMBINATION THERAPY.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12014500381A1 (en) Therapeutic methods
MX2022000394A (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
Huard Ribavirin/sofosbuvir
MX2013009456A (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis.
IL286029A (en) Potassium-binding agents for use in hemodialysis patients
Mekinian Infliximab/tocilizumab
Ocvirk Capecitabine/cetuximab/irinotecan
Markhorst Headache: case report
Hayakawa Tegafur/uracil
Cathomas Denosumab/sorafenib